$60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Lobbying related to domestic pharmaceutical supply federal budget issues"
You can find more data on corporate lobbying on Quiver Quantitative.
AMRX Hedge Fund Activity
We have seen 175 institutional investors add shares of AMRX stock to their portfolio, and 102 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 10,220,672 shares (+71.5%) to their portfolio in Q1 2026, for an estimated $127,042,952
- CITADEL ADVISORS LLC removed 5,598,318 shares (-90.7%) from their portfolio in Q1 2026, for an estimated $69,587,092
- MILLENNIUM MANAGEMENT LLC removed 2,990,465 shares (-89.0%) from their portfolio in Q1 2026, for an estimated $37,171,479
- STATE STREET CORP added 2,684,292 shares (+65.3%) to their portfolio in Q1 2026, for an estimated $33,365,749
- RUBRIC CAPITAL MANAGEMENT LP removed 1,297,352 shares (-10.5%) from their portfolio in Q1 2026, for an estimated $16,126,085
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,273,997 shares (-96.0%) from their portfolio in Q1 2026, for an estimated $15,835,782
- ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC added 1,069,400 shares (+72.2%) to their portfolio in Q1 2026, for an estimated $13,292,642
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AMRX Price Targets
Multiple analysts have issued price targets for $AMRX recently. We have seen 3 analysts offer price targets for $AMRX in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $16.0 on 05/20/2026
- Ashwani Verma from UBS set a target price of $19.0 on 04/17/2026
- Les Sulewski from Truist Securities set a target price of $17.0 on 03/02/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
